<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02034669</url>
  </required_header>
  <id_info>
    <org_study_id>TP-VD-2012</org_study_id>
    <nct_id>NCT02034669</nct_id>
  </id_info>
  <brief_title>Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Spinal Cord Injury Treatment</brief_title>
  <official_title>A Phase II Study of Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Completely Acute Spinal Cord Injury.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tri Phuoc Biotechnology., JSC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tri Phuoc Biotechnology., JSC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety and effect of autologous adipose derived stem&#xD;
      cell (ADSCs) transplantation in acute spinal cord injury patients.&#xD;
&#xD;
        1. To assess the safety of autologous ADSCs transplantation in acute spinal cord injury and&#xD;
           the complication after ADSCs transplantation.&#xD;
&#xD;
        2. To evaluate the effect of ADSCs isolation and expansion procedure.&#xD;
&#xD;
        3. To determine if functional outcome is improved following ADSCs transplantation in acute&#xD;
           spinal cord injury patient, using pre-transplantation spinal cord function as the&#xD;
           control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research has carried out in Phase II which is designed as randomized controlled trials.&#xD;
&#xD;
      Selection of patients began in Feb,2013, 48 patients are divided in two group according to a&#xD;
      2:1 ratio (the number of candidates as treated: the candidates as control).&#xD;
&#xD;
      The effectiveness of preliminary trial are evaluated by assessing Frankel/ASIA motor grade,&#xD;
      measuring electrophysiological parameters, enhanced MRI and urinary and bowel function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with adverse events after transplantation.</measure>
    <time_frame>24 months</time_frame>
    <description>Number of Participants with adverse events is as a measure of safety and tolerability after ADSC transplantation. Adverse events can be impaired liver and kidney, immunosuppression or immune deficiency, hypersensitivity, anaphylactic shock, meningitis symptoms, etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of spinal cord edema in the MRI at the lesion site</measure>
    <time_frame>24 months</time_frame>
    <description>Patients take MRI at the lesion site before each injection and after transplantation 6 months, 12 months, 24 months. MRI at the lesion site shows spinal cord edema level is reduced or not.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary and bowel function Improvement</measure>
    <time_frame>24 months</time_frame>
    <description>Bladder pressure monitory to assess ability to feel and control urination and bowel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle contraction force measurement</measure>
    <time_frame>24 months</time_frame>
    <description>Comparison the electromyography (EMG) score during contraction of given muscles before each injection and after transplantation 6 months, 12 months and 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant clinical improvement in ASIA impairment scale and general condition.</measure>
    <time_frame>24 months</time_frame>
    <description>Patients are assess improvement level based on American Spinal Injury Assessment scale of A,B,C,D or E before and after transplantation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Acute Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Treatment with ADSCs transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 Intervention: laminectomy, intradural space at damage site, intrathecal at lumbar puncture, intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment without ADSCs transplantation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Only intervention: laminectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laminectomy</intervention_name>
    <description>surgical laminectomy with glial scar resection</description>
    <arm_group_label>Treatment with ADSCs transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intradural space</intervention_name>
    <description>ADSCs injection into Intradural space at damage site</description>
    <arm_group_label>Treatment with ADSCs transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intrathecal</intervention_name>
    <description>ADSCs Intrathecal into lumbar puncture</description>
    <arm_group_label>Treatment with ADSCs transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intravenous</intervention_name>
    <description>ADSCs intravenous</description>
    <arm_group_label>Treatment with ADSCs transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be able to give voluntary (patients may not be able to write) consent.&#xD;
&#xD;
          -  Must be able to understand study information provided to him.&#xD;
&#xD;
          -  Patients with complete spinal cord &lt; 2 weeks in acute category&#xD;
&#xD;
          -  The level of spinal cord injury must be categorized at A level in terms of ASIA&#xD;
             Impairment scale.&#xD;
&#xD;
          -  Age should be between 19-60 years&#xD;
&#xD;
          -  Both male and female&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Support respiration by machine&#xD;
&#xD;
          -  Melanoma within 5 years&#xD;
&#xD;
          -  Infectious diseases including HIV and Hepatitis B, C&#xD;
&#xD;
          -  Brain damage or multiple trauma&#xD;
&#xD;
          -  Body temperature higher 38 â„ƒ or acute disorder&#xD;
&#xD;
          -  Anemia or thrombocytopenia&#xD;
&#xD;
          -  Angina , myocardial infarction , heart disease , embolic disease , chronic renal&#xD;
             failure, glomerular disease and chronic obstructive pulmonary disease.&#xD;
&#xD;
          -  Congenital or acquired immunodeficiency disorder&#xD;
&#xD;
          -  Muscular dystrophy or muscle stiffness&#xD;
&#xD;
          -  Non-conscious or voice disorders&#xD;
&#xD;
          -  Treatment with cytotoxic drugs ( immunosuppressive drugs , corticosteroids and&#xD;
             cytotoxic drugs) during the clinical trials .&#xD;
&#xD;
          -  Participating in another clinical trial within 3 months&#xD;
&#xD;
          -  Other serious disease or disorder can seriously affect the ability to participate in&#xD;
             research.&#xD;
&#xD;
          -  Women who are pregnant or lactating .&#xD;
&#xD;
          -  Allergy to antibiotics and anesthetics .&#xD;
&#xD;
          -  Do not agree to participate in research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phuc Ba Duong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tri Phuoc Biotechnology., JSC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hoa D Nguyen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vietnamese- German Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Phuc Ba Duong, MD</last_name>
    <phone>+17143607716</phone>
    <email>triphuocbio@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hoa D Nguyen, MD</last_name>
    <phone>+84904613833</phone>
    <email>dinhhoaykhoa@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vietnamese- German Hospital</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phuc Ba Duong, MD</last_name>
      <phone>+17143607716</phone>
      <email>triphuocbio@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hoa D Nguyen, MSc, MD</last_name>
      <phone>+84904613833</phone>
      <email>dinhhoaykhoa@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>January 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2014</study_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Spinal cord Injury, Adipose derived stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

